DR.REDDY'S LABORATORIES LTD.

Dr Reddy's Laboratories Ltd announced that certain batches of its semaglutide product were found to be out of specification due to an issue with the active pharmaceutical ingredient (API). The company is investigating the root cause and implementing corrective measures. Commercial supplies of the product will be temporarily delayed. Importantly, there is no impact on patient safety or existing global regulatory filings. Dr Reddy's remains committed to reliable global supplies of this metabolic therapy and will host a conference call to discuss the matter.

Dr Reddy's Laboratories Ltd has announced its 42nd Annual General Meeting (AGM) to be held on July 23, 2026, via Video Conferencing. The Integrated Annual Report for FY 2025-26 is available online. The company also declared a final dividend of ₹8 per equity share for FY 2025-26, with a record date of July 10, 2026, and payment on or before July 30, 2026. Shareholders are advised to update their KYC details. E-voting will be open from July 19 to July 22, 2026.

Dr Reddy's Laboratories Ltd has announced its 42nd Annual General Meeting (AGM) to be held on Thursday, July 23, 2026, at 11:00 AM IST via Video Conferencing. Key agenda items include the adoption of audited financial statements for FY26, declaration of a final dividend of ₹8 per equity share, re-appointment of Mr. K Satish Reddy as Director, and appointment of M/s. Deloitte Haskins & Sells, LLP as Statutory Auditors for five years. The notice also details e-voting procedures and timelines, with e-voting commencing on July 19, 2026, and concluding on July 22, 2026. The cut-off date for determining voting rights is July 16, 2026.

Dr Reddy's Laboratories Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as mandated by SEBI regulations. The report, an integral part of the company's Integrated Annual Report, details key performance indicators across environmental, social, and governance (ESG) principles. Highlights include significant employee training on ethical conduct and ESG goals, a 100% sourcing from suppliers adhering to the Third Party Code of Conduct, and 98% of global waste diverted from landfills. The company also reported a 50% absolute reduction target for Scope 1 & 2 emissions from a 2023 baseline and 78% electricity consumption from renewable sources. Employee well-being is emphasized with high rates of insurance coverage, return-to-work post-parental leave, and skill upgradation training.

Dr Reddy's Laboratories Ltd has submitted its Integrated Annual Report for the financial year 2025-26, in compliance with the Companies Act, 2013 and SEBI Listing Regulations. The report, which includes the Business Responsibility and Sustainability Report (BRSR) and the Notice of the 42nd Annual General Meeting (AGM), is being sent electronically to registered members. A web-link is provided for members whose email addresses are not registered. The report covers corporate overview, strategic review, financial statements, sustainability initiatives, and governance reports, accessible via the company's website. The theme highlights 'Strengthening the Core. Building the Future. Good Health Can’t Wait.'

Dr Reddy's Laboratories Ltd announced that the United States Food & Drug Administration (USFDA) has completed a Pre-License Inspection (PLI) at its biologics manufacturing facility in Bachupally, Hyderabad. The inspection, conducted from June 16 to June 25, 2026, resulted in the issuance of a Form 483 with seven observations. The company stated it will address these observations within the stipulated timeline. This inspection follows previous ones, with disclosures made on October 12, 2023, and September 13, 2025.

Dr Reddy's Laboratories Ltd has announced the closure of its trading window from June 24, 2026, to July 24, 2026. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The decision precedes a Board of Directors meeting scheduled for July 22, 2026, where the company will consider its Un-audited Standalone and Consolidated Financial Results for the quarter ending June 30, 2026. The trading window will reopen on July 25, 2026.

Dr Reddy's Laboratories Ltd has announced that its Board of Directors will convene on July 22, 2026. The primary agenda item is to consider and approve the Un-audited Standalone and Consolidated Financial Results for the first quarter ending June 30, 2026. Additionally, the company has informed that the trading window for its securities will be closed from June 24, 2026, to July 24, 2026, inclusive, in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015.

Dr. Reddy's Laboratories has announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. This launch expands the company's oncology portfolio and aims to improve patient access to affordable medicines. The product is a first-to-file generic eligible for 180-day exclusivity. Dr. Reddy's holds exclusive marketing rights, while MSN Laboratories developed and manufactured the product. The Bosulif® brand had U.S. sales of approximately $253.8 million for the 12 months ended April 2026.

Dr. Reddy's Laboratories Ltd has filed its Annual Report in Form 20-F for the fiscal year ended March 31, 2026, with the United States Securities and Exchange Commission on May 30, 2026. The report, containing annual consolidated financial statements prepared under International Financial Reporting Standards (IFRS), is available on the company's website.